Cure My Disease

Don't miss your cure!

 Log in / Sign up

Do newer hemophilia drugs protect joints better? study aims to find out

NCT ID NCT07692217

Not yet recruiting Knowledge-focused Sponsor: University of Texas Southwestern Medical Center Source: ClinicalTrials.gov ↗

First seen Jul 09, 2026 · Last updated Jul 10, 2026 · Updated 1 time

Summary

This observational study looks at children with moderate or severe hemophilia A who are on one of two preventive treatments: a longer-acting factor VIII therapy (efanesoctocog alfa) or a non-factor therapy (emicizumab). Researchers want to see if there are differences in how well the blood clots and whether tiny joint bleeds lead to early joint damage. The goal is to understand if one treatment offers better protection for joints over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
efanesoctocog alfa (Altuviiio) and emicizumab (Hemlibra)
What this could lead to
If differences are found, this could help doctors choose the best treatment for each child to prevent joint damage.
What could go wrong
This is an observational study, not a treatment trial, so it won't directly change care. Results may show no clear difference between the two drugs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FACTOR VIII (FVIII) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hemophilia A

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FACTOR VIII (FVIII) HEMOPHILIA A

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The University of Texas Southwestern Medical Center

    Dallas, Texas, 75235, United States

    Contact

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.